Article Details

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Retrieved on: 2025-03-12 20:42:13

Tags for this article:

Click the tags to see associated articles and topics

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results. View article details on hiswai:

Summary

The article highlights Nektar Therapeutics' progress in developing rezpegaldesleukin, a treatment for autoimmune diseases including alopecia areata and type 1 diabetes. It illustrates their financial growth, research initiatives, and strategic plans.

Article found on: www.tradingview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up